Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155777 · ClinicalTrials.gov registry record · Early Phase 1
Why do Oral Contraceptives Prevent Ovarian Cancer?
A Early Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
NCT02155777 is a Early Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 52 participants.
The verdict
NCT02155777, a Early Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Use of oral contraceptives (OCs) reduces a woman's risk of ovarian cancer very significantly and the protective effect continues for at least 25 years after use of OCs is stopped; the mechanisms of how this occurs are not understood. We are proposing here to directly study the effect of OCs on the fallopian tube and inclusion cysts within the ovary - sites from which most ovarian cancers are thought to arise - in order to better understand the mechanistic basis for OC protection against ovarian cancer. We think the protection results from reduced cell proliferation. It will lay the foundation for further studies to ensure that the protection against ovarian cancer afforded by 'traditional' OCs is not lost with alterations in OC formulation, and, if possible, to guide development of OC formations to improve further on the protection afforded by OCs.
Interventions
- DRUG OrthoNovum 1/35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155777
The ClinicalTrials.gov registry entry for NCT02155777 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OrthoNovum 1/35 is the first listed.
NCT02155777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155777 about?
NCT02155777 is a clinical study titled "Why do Oral Contraceptives Prevent Ovarian Cancer?". Use of oral contraceptives (OCs) reduces a woman's risk of ovarian cancer very significantly and the protective effect continues for at least 25 years after use of OCs is stopped; the mechanisms of how this occurs are not understood. We are proposing here to directly study the effect of OCs on the f...
What is the current status of trial NCT02155777?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2014-06. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02155777?
The interventions under investigation include: OrthoNovum 1/35 (DRUG).
Who is sponsoring clinical trial NCT02155777?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.